Trial Profile

Cemiplimab Survivorship Epidemiology (CASE) Study

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 02 Nov 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Cemiplimab (Primary)
Indications Basal cell cancer; Skin cancer; Squamous cell cancer
Focus Adverse reactions; Therapeutic Use
Acronyms CASE
Sponsors Regeneron Pharmaceuticals

Most Recent Events

27 Sep 2023 Planned End Date changed from 30 Sep 2025 to 28 Oct 2025.
27 Sep 2023 Planned primary completion date changed from 30 Sep 2025 to 28 Oct 2025.
06 Jun 2023 Trial design presented at the 59th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com